US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kairos Pharma, Ltd.

0.8114

-0.0306-3.63%

Volume:60.73K

Turnover:50.40K

Market Cap:13.54M

PE:-3.54

High:0.8650

Open:0.8650

Low:0.8102

Close:0.8420

Loading ...

Overview Company News Filings

Kairos Pharma Ltd. Announces Change in Certifying Accountants, Dismisses Marcum LLP

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

BRIEF-Kairos Pharma Remains Financially Strong Despite Recent Economic Headwinds

Kairos Pharma Ltd - Remains Financially Strong Despite Recent Economic Headwinds

THOMSON REUTERS

Kairos Pharma Ltd. Provides Letter to Stockholders

Kairos Pharma files to sell 16.29M shares of common stock for holders

BRIEF-Kairos Pharma Announces Department Of Defense Grant To Support Its Study Of Lead Compound Env105 To Prevent Drug Resistance In Lung Cancer

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound Env105 to Prevent Drug Resistance in Lung Cancer

THOMSON REUTERS

Kairos Pharma Is Maintained at Buy by D. Boral Capital

HC Wainwright Initiates Kairos Pharma at Buy With $12 Price Target

MT Newswires Live

Kairos Pharma: Promising Oncology Pipeline and Strategic Advancements Drive Buy Rating

Kairos Pharma: Promising Innovations in Cancer Drug Resistance and Immune Enhancement

Top Calls on Wall Street: Nvidia, Block, Lyft, Best Buy, RH, Zscaler, Ross Stores and More

Kairos Pharma Initiated at Buy by HC Wainwright & Co.

Kairos Pharma initiated with a Buy at H.C. Wainwright

Kairos Pharma, Ltd. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

Kairos Pharma Is Maintained at Buy by D. Boral Capital

BRIEF-Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of Env105 in Metastatic, Castration-Resistant Prostate Cancer

THOMSON REUTERS

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KAPA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KAPA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","market":"US","secType":"STK","nameCN":"Kairos Pharma, Ltd.","latestPrice":0.8114,"timestamp":1745956800000,"preClose":0.842,"halted":0,"volume":60726,"delay":0,"floatShares":1550000,"shares":16693306,"eps":-0.229208,"marketStatus":"Pre-Mkt","change":-0.0306,"latestTime":"04-30 04:51:55 EDT","open":0.865,"high":0.865,"low":0.8102,"amount":50396.785297,"amplitude":0.065083,"askPrice":0.975,"askSize":105,"bidPrice":0.8114,"bidSize":163,"shortable":3,"etf":0,"ttmEps":-0.229208,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746019800000},"marketStatusCode":1,"adr":0,"listingDate":1717992000000,"exchange":"NASDAQ","adjPreClose":0.8114,"postHourTrading":{"tag":"盘后","latestPrice":0.8118,"preClose":0.8114,"latestTime":"19:48 EDT","volume":401,"amount":325.555,"timestamp":1745970526732},"volumeRatio":0.5484237951385237},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","floatShares":1550000,"roa":"-43.50%","roe":"-192.96%","lyrEps":-0.229208,"volumeRatio":0.5484237951385237,"shares":16693306,"dividePrice":0,"high":0.865,"amplitude":0.065083,"preClose":0.842,"low":0.8102,"week52Low":0.8021,"pbRate":"2.84","week52High":4,"institutionHeld":0,"latestPrice":0.8114,"committee":0.216418,"eps":-0.229208,"divideRate":0,"volume":60726,"delay":0,"ttmEps":-0.229208,"open":0.865,"prevYearClose":1.52,"prevWeekClose":0.867,"prevMonthClose":0.9362,"prevQuarterClose":0.9362,"fiveDayClose":0.8948,"twentyDayClose":0.9362,"sixtyDayClose":1.43},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KAPA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531293219","title":"Kairos Pharma Ltd. Announces Change in Certifying Accountants, Dismisses Marcum LLP","url":"https://stock-news.laohu8.com/highlight/detail?id=2531293219","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531293219?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:29","pubTimestamp":1745875762,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. has announced a change in its certifying accountants as part of its recent financial reporting update. On April 23, 2025, the company's audit committee appointed Weinberg and Company, P.A. as its new independent registered public accounting firm for the fiscal year ending December 31, 2025. This decision resulted in the dismissal of Marcum LLP, effective on the same date. Marcum's audit reports for the years ended December 31, 2024, and 2023 included no adverse opinions or disclaimers, although the 2023 report noted uncertainty regarding the company's ability to continue as a going concern. There were no disagreements or reportable events with Marcum regarding accounting principles or practices. This transition follows the identification of material weaknesses in internal controls over financial reporting for the fiscal years 2024 and 2023.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nNDL4LKfLx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","CBZ","LU2065732104.USD","BK4123","BK4139"],"gpt_icon":0},{"id":"2530097104","title":"Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530097104","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530097104?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"LOS ANGELES, April 28, 2025----Kairos Pharma, Ltd. , a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology  2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill.John Yu, M.D., Kairos CEO commented, \"We look forward to the opportunity to continue to share data regarding our platform assets at one of the most prestigious oncology meetings in the world. We believe that KROS 101 has the potential to help optimize cancer treatment and we look forward to discussing our findings with the medical and scientific communities.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-ltd-announces-data-120000153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4117","KAPA","KAIR","BK4139","BK4107"],"gpt_icon":0},{"id":"2529532981","title":"BRIEF-Kairos Pharma Remains Financially Strong Despite Recent Economic Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=2529532981","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529532981?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:21","pubTimestamp":1745497305,"startTime":"0","endTime":"0","summary":"BRIEF-Kairos Pharma Remains Financially Strong Despite Recent Economic HeadwindsApril 24 (Reuters) - Kairos Pharma Ltd KAPA.A:KAIROS PHARMA LTD - REMAINS FINANCIALLY STRONG DESPITE RECENT ECONOMIC HEA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R21AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2529986054","title":"Kairos Pharma Ltd - Remains Financially Strong Despite Recent Economic Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986054?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:11","pubTimestamp":1745496711,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R21AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2529098694","title":"Kairos Pharma Ltd. Provides Letter to Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2529098694","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529098694?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"LOS ANGELES, April 24, 2025----Kairos Pharma, Ltd. , a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.:. As we reflect on the Company’s progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future holds.Despite recent economic headwinds, we remain financially strong due to our recent private placement and judicious use of funds with non-dilutive funding. Thank you for your continued support and confidence in our mission. We look forward to providing you with regular updates on our progress","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-ltd-provides-letter-120000161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KAIR","BK4139","KAPA"],"gpt_icon":0},{"id":"2529373311","title":"Kairos Pharma files to sell 16.29M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2529373311","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529373311?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:10","pubTimestamp":1745316635,"startTime":"0","endTime":"0","summary":"06:05 EDT Kairos Pharma (KAPA) files to sell 16.29M shares of common stock for holders Published first on TheFly – the ultimate source for real-tim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-files-to-sell-16-29m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-files-to-sell-16-29m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","BK4139","KAIR"],"gpt_icon":0},{"id":"2528159712","title":"BRIEF-Kairos Pharma Announces Department Of Defense Grant To Support Its Study Of Lead Compound Env105 To Prevent Drug Resistance In Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2528159712","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528159712?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:59","pubTimestamp":1744894750,"startTime":"0","endTime":"0","summary":"BRIEF-Kairos Pharma Announces Department Of Defense Grant To Support Its Study Of Lead Compound Env105 To Prevent Drug Resistance In Lung CancerApril 17 (Reuters) - Kairos Pharma Ltd KAPA.A:KAIROS PHA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA36FRPP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2528161167","title":"Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound Env105 to Prevent Drug Resistance in Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2528161167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528161167?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:00","pubTimestamp":1744891204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA36FRPP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2528713034","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2528713034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528713034?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:36","pubTimestamp":1744889760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 17, 2025 07:36 ET (11:36 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2527625213","title":"HC Wainwright Initiates Kairos Pharma at Buy With $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2527625213","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527625213?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:59","pubTimestamp":1744804785,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Kairos Pharma at Buy With $12 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2527939382","title":"Kairos Pharma: Promising Oncology Pipeline and Strategic Advancements Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2527939382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527939382?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:16","pubTimestamp":1744798612,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kairos Pharma, Ltd. (KAPA – Research Report) and keeping the price target ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kairos-pharma-promising-oncology-pipeline-and-strategic-advancements-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kairos-pharma-promising-oncology-pipeline-and-strategic-advancements-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2524296998","title":"Kairos Pharma: Promising Innovations in Cancer Drug Resistance and Immune Enhancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2524296998","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524296998?lang=en_us&edition=fundamental","pubTime":"2025-04-04 01:05","pubTimestamp":1743699915,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. (KAPA) has received a new Buy rating, initiated by H.C. Wainwright analyst, Joseph Pantginis. Joseph Pantginis has given his Bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kairos-pharma-promising-innovations-in-cancer-drug-resistance-and-immune-enhancement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kairos-pharma-promising-innovations-in-cancer-drug-resistance-and-immune-enhancement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAIR","KAPA"],"gpt_icon":0},{"id":"1105265075","title":"Top Calls on Wall Street: Nvidia, Block, Lyft, Best Buy, RH, Zscaler, Ross Stores and More","url":"https://stock-news.laohu8.com/highlight/detail?id=1105265075","media":"The Fly","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105265075?lang=en_us&edition=fundamental","pubTime":"2025-04-03 23:30","pubTimestamp":1743694200,"startTime":"0","endTime":"0","summary":"The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades:Morga","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thefly.com/landingPageNews.php?id=4099879&headline=XYZ;ZS;ROST;TJX;FAST;NVDA;LYFT;RXST;RH;BBY;SNDK;ESI;TALK;EQBK;KAPA-Block-upgraded-Nvidia-downgraded-Wall-Streets-top-analyst-calls&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1649979459173","symbols":["NVDA","KAPA","LYFT","ROST","RXST","TALK","XYZ","ZS","RH","BBY","FAST","SNDK","EQBK","TJX","ESI"],"gpt_icon":1},{"id":"2524123770","title":"Kairos Pharma Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524123770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524123770?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:01","pubTimestamp":1743678060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 07:01 ET (11:01 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA","KAIR"],"gpt_icon":0},{"id":"2524234948","title":"Kairos Pharma initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2524234948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524234948?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:16","pubTimestamp":1743675383,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $12 price target The company’s oncology pipeline “could unlock the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","BK4139","KAPA"],"gpt_icon":0},{"id":"2524391882","title":"Kairos Pharma, Ltd. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2524391882","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524391882?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:03","pubTimestamp":1743674628,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nAZN3NMNXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2523499149","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2523499149","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523499149?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:39","pubTimestamp":1743424740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 08:39 ET (12:39 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2523917211","title":"BRIEF-Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917211","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917211?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:13","pubTimestamp":1743419608,"startTime":"0","endTime":"0","summary":"BRIEF-Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate CancerMarch 31 (Reuters) - Kairos Pharma ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA5JVFJG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2523452912","title":"Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of Env105 in Metastatic, Castration-Resistant Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523452912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523452912?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA5JVFJG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2522531125","title":"Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2522531125","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522531125?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"LOS ANGELES, March 27, 2025----Kairos Pharma, Ltd. , a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and announces participation in future events.March 12, 2025 – Presented at the Society for Immunotherapy of Cancer Spring Scientific Meeting titled, \"Novel GITR Agonist KROS 101: A Dual Approach to Boost T Cell Immunity and Alter the Tumor Microenvironment\". March 17 to 19 – Participated in the BIO Europe conference in Milan, Italy. April 29 to May 1 – Kairos is slated to participate at the Fierce Pharma Engage Business Development and Licensing Meeting in San Diego. This press release contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as \"may,\" \"should,\" \"expects,\" \"anticipates,\" \"contemplates,\" \"estimates,\" \"believes,\" \"plans,\" \"projected,\" \"predicts,\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-ltd-highlights-participation-200500406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KAIR","BK4139","KAPA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KAPA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KAPA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KAPA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1743739200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KAPA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KAPA","date":"2025-04-28","current":-5.56016,"percent":0.75817,"low":-25.607053,"twenty":-9.014963,"median":-7.194387,"eighty":-5.181171,"high":-4.54629,"avg":-7.715903,"sd":3.15831,"marketCap":14473096},"quantilePoints":[{"date":"2024-09-13","current":-25.607053,"twenty":-25.607053,"median":-25.607053,"eighty":-25.607053,"marketCap":51367748},{"date":"2024-09-20","current":-14.59602,"twenty":-25.607053,"median":-16.196461,"eighty":-14.724055,"marketCap":29279616},{"date":"2024-09-27","current":-10.594918,"twenty":-16.644584,"median":-14.59602,"eighty":-12.803526,"marketCap":21253405},{"date":"2024-10-04","current":-8.706398,"twenty":-15.748337,"median":-12.835535,"eighty":-9.858715,"marketCap":17465034},{"date":"2024-10-11","current":-9.410592,"twenty":-14.724055,"median":-10.594918,"eighty":-8.706398,"marketCap":18877647},{"date":"2024-10-18","current":-9.410592,"twenty":-14.59602,"median":-9.890724,"eighty":-9.026486,"marketCap":18877647},{"date":"2024-10-25","current":-9.602645,"twenty":-14.019861,"median":-9.73068,"eighty":-9.026486,"marketCap":19262905},{"date":"2024-10-31","current":-8.64238,"twenty":-13.098007,"median":-9.602645,"eighty":-8.947104,"marketCap":17336614},{"date":"2024-11-08","current":-8.770415,"twenty":-12.81633,"median":-9.464686,"eighty":-8.64238,"marketCap":17593453},{"date":"2024-11-15","current":-13.158824,"twenty":-13.152678,"median":-9.474609,"eighty":-8.64238,"marketCap":26396601},{"date":"2024-11-22","current":-7.030345,"twenty":-12.924264,"median":-9.410592,"eighty":-8.578362,"marketCap":19270177},{"date":"2024-11-29","current":-7.217821,"twenty":-12.829133,"median":-9.282556,"eighty":-8.469532,"marketCap":19784048},{"date":"2024-12-06","current":-6.608525,"twenty":-12.265778,"median":-9.026486,"eighty":-7.967725,"marketCap":18113966},{"date":"2024-12-13","current":-8.061463,"twenty":-11.119862,"median":-8.738406,"eighty":-7.667763,"marketCap":22096470},{"date":"2024-12-20","current":-7.920856,"twenty":-10.268428,"median":-8.706398,"eighty":-7.780249,"marketCap":21711066},{"date":"2024-12-27","current":-7.827118,"twenty":-9.999554,"median":-8.64238,"eighty":-7.780249,"marketCap":21454130},{"date":"2025-01-03","current":-7.170953,"twenty":-9.909929,"median":-8.578362,"eighty":-7.46154,"marketCap":19655581},{"date":"2025-01-10","current":-4.827504,"twenty":-9.858715,"median":-8.578362,"eighty":-7.311559,"marketCap":13232188},{"date":"2025-01-17","current":-8.295808,"twenty":-9.858715,"median":-8.530349,"eighty":-7.261949,"marketCap":22738809},{"date":"2025-01-24","current":-7.311559,"twenty":-9.756287,"median":-8.373067,"eighty":-7.264142,"marketCap":20040984},{"date":"2025-01-31","current":-6.936607,"twenty":-9.73068,"median":-8.108332,"eighty":-7.170953,"marketCap":19013241},{"date":"2025-02-07","current":-6.749132,"twenty":-9.628252,"median":-8.036517,"eighty":-7.161579,"marketCap":18499370},{"date":"2025-02-14","current":-6.796001,"twenty":-9.602645,"median":-7.967725,"eighty":-7.030345,"marketCap":18627838},{"date":"2025-02-21","current":-6.233573,"twenty":-9.526207,"median":-7.967725,"eighty":-7.030345,"marketCap":17086224},{"date":"2025-02-28","current":-5.671145,"twenty":-9.474865,"median":-7.897422,"eighty":-6.869431,"marketCap":15544609},{"date":"2025-03-07","current":-5.198227,"twenty":-9.462702,"median":-7.803684,"eighty":-6.730384,"marketCap":14248340},{"date":"2025-03-14","current":-4.773372,"twenty":-9.428261,"median":-7.780249,"eighty":-6.44917,"marketCap":13083812},{"date":"2025-03-21","current":-4.898329,"twenty":-9.410592,"median":-7.639642,"eighty":-6.289816,"marketCap":13426320},{"date":"2025-03-28","current":-4.848346,"twenty":-9.33377,"median":-7.452166,"eighty":-6.092966,"marketCap":13289317},{"date":"2025-04-04","current":-4.698397,"twenty":-9.282556,"median":-7.358428,"eighty":-5.577408,"marketCap":12878307},{"date":"2025-04-11","current":-4.948312,"twenty":-9.244146,"median":-7.311559,"eighty":-5.297393,"marketCap":13563323},{"date":"2025-04-17","current":-4.775903,"twenty":-9.141718,"median":-7.263319,"eighty":-5.121191,"marketCap":12431676},{"date":"2025-04-25","current":-5.470376,"twenty":-9.018804,"median":-7.217821,"eighty":-5.172643,"marketCap":14239390},{"date":"2025-04-28","current":-5.56016,"twenty":-9.014963,"median":-7.194387,"eighty":-5.181171,"marketCap":14473096}],"updateTime":1745992260887}}}